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Abstract Background Ceruminal gland carcinomas are
rare neoplasms conﬁned to the skin lining the cartilaginous
part of the external auditory canal. Design Retrospective.
Results The patients included 11 men and 6 women, aged
33–82 years (mean, 59.5 years). Patients presented clini-
cally with a mass of the outer half of the external auditory
canal (n = 14), hearing changes (n = 5), drainage (n = 4),
or paralysis of the facial nerve (n = 3). The polypoid
masses ranged in size from 0.5 to 3 cm in greatest
dimension (mean, 1.8 cm). Histologically, the tumors
demonstrated a solid to cystic pattern, composed of an
inﬁltrating glandular to cribriform arrangement of epithe-
lial cells. Histologic features included a dual cell
population (although not the dominant histology),
increased cellularity, moderate to severe nuclear pleomor-
phism, irregular nucleoli, increased mitotic ﬁgures (mean,
3/10 HPF), including atypical forms, and tumor necrosis
(n = 2). Tumors were divided into three types of adeno-
carcinoma based on pattern of growth and cell type
(ceruminous, NOS [n = 12], adenoid cystic [n = 4],
mucoepidermoid [n = 1]). CK7 and CD117 highlighted
the luminal cells, while S1-00 protein showed a predilec-
tion for the basal cells of ceruminous and adenoid cystic
carcinomas. Metastatic adenocarcinoma or direct extension
from salivary gland neoplasms are the principle differential
considerations. Surgical resection was used in all patients
with radiation used in four patients. Eleven patients were
alive or had died of unrelated causes without evidence of
disease (mean, 11.2 years); six patients had died with
disease (mean, 4.9 years), all of whom had developed local
recurrence. Conclusion Ceruminous-type carcinomas, with
the exception of ceruminous mucoepidermoid carcinoma,
all demonstrated a dual cell population of basal myoepi-
thelial-type cells and luminal apocrine cells. The speciﬁc
histologic sub-type does not inﬂuence the long-term patient
outcome.
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Introduction
Tumors arising from the ceruminal glands of the external
ear canal can present a diagnostic dilemma because of their
varied clinical and histological manifestations. While
common in other animals [1], tumors of this type are rare in
humans and therefore are seldom seen by general surgical
pathologists [2, 3]. In fact, glandular external auditory
canal tumors represent 0.00025% of all cases at one large
referral institution [4], and represented 2.4% of all ear
neoplasms at our referral institution. Further adding to the
confusion for pathologists and clinicians alike, is the var-
iable nomenclature used to synonymously describe both
benign and malignant tumors of ceruminal gland origin
(Table 1)[ 5–16]. The varied clinical behavior, treatment
alternatives, and long-term patient prognosis of the
N. Crain  L. D. R. Thompson (&)
Department of Pathology, Southern California Permanente
Medical Group, Woodland Hills Medical Center, 5601 De Soto
Avenue, Woodland Hills, CA 91367-6701, USA
e-mail: Lester.D.Thompson@kp.org
B. L. Nelson
Pathology Department, Naval Medical Center, San Diego, CA,
USA
E. L. Barnes
Department of Pathology, Presbyterian University Hospital,
Pittsburgh, PA, USA
Head and Neck Pathol (2009) 3:1–17
DOI 10.1007/s12105-008-0095-9different types of ceruminal gland neoplasms necessitates
more speciﬁc diagnostic terminology. While there have
been a few series a few decades ago [4, 9, 17, 18], there are
only a limited number of case reports in the English liter-
ature (Table 2), which is otherwise devoid of a large
comprehensive evaluation of ceruminous-type adenocarci-
nomas with respect to their histomorphology,
immunohistochemical reactivity, treatment outcomes, and
clinical behavior. We undertook this study in an attempt to
identify any speciﬁc features which can be used to separate
benign from malignant ceruminous tumors and to deter-
mine the best nomenclature to yield a meaningful clinical
management impact.
Methods
The records of 17 patients with tumors diagnosed as
ceruminal adenocarcinoma, ceruminal adenoid cystic car-
cinoma, mucoepidermoid carcinoma, and adenocarcinoma
of the external ear canal were selected. The cases were
retrieved from the ﬁles of the Otorhinolaryngic-Head &
Neck Tumor Registry of the Armed Forces Institute of
Pathology (AFIP), Washington, DC, between 1970 and
2000. These 17 cases were chosen from a review of 723
(2.4%) benign or malignant primary ear tumors seen in
consultation during this time. Due to the nature of our
consultation service, we were not able to separate tumors
arising from the external ear versus external auditory canal
in attempting to determine the incidence data. Sufﬁce it to
say that ceruminal malignancies are uncommon. Fifteen
cases were obtained from civilian sources, including uni-
versity medical centers and foreign contributors, one case
from a military hospital, and one case from a Veterans
Administration medical center.
Materials within the Institute’s ﬁles were supplemented
by a review of the patient demographics (gender, age);
symptoms and physical ﬁndings and duration at presenta-
tion including mass, hearing loss, bleeding, infection, pain,
headaches, weakness, syncope or dizziness, nerve paraly-
sis, discharge, equilibrium changes, tinnitus and/or
popping, visual changes; and past medical and surgical
history. In addition, we reviewed radiographic, surgical
pathology, and operative reports and obtained follow-up
information from oncology data services by written ques-
tionnaires or direct communication with the treating
physician(s) or the patient. Follow-up data, available for all
patients, included information regarding tumor location,
presence of recurrent disease, treatment modalities used,
and the current patient status. This clinical investigation
was conducted in accordance and compliance with all
statutes, directives, and guidelines of the Code of Federal
Regulations, Title 45, Part 46, and the Department of
Defense Directive 3216.2 relating to human subjects in
research.
The macroscopic pathology observations noted within
this study were gathered from the individual gross
descriptions of the neoplasms given by the contributing
pathologists. Hematoxylin and eosin-stained slides from all
cases were reviewed, with speciﬁc histologic features
annotated as follows: exact tumor location; lateralization;
tumor size (greatest dimension in centimeters); tumor
encapsulation (presence or absence); tumor extension
(mastoid bone, eustachian tube, and/or middle ear); archi-
tectural pattern of growth (solid, papillary, cystic
inﬁltrating, glandular); dual cell population; surface origin;
surface ulceration; presence or absence of necrosis; tumor
cellularity (low, moderate, or high); cellular pleomorphism
(mild, moderate, severe); presence of nucleoli; mitotic
ﬁgures (number of mitotic ﬁgures per 10 high power ﬁelds
[magniﬁcation at 940 with a 910 objective lens using an
Olympus BX40 microscope]); atypical mitotic ﬁgures
(present or absent, and deﬁned by abnormal chromosome
spread, tripolar or quadripolar forms, circular forms, or
indescribably bizarre); ceruminal apocrine decapitation
secretion; cerumen (wax) eosinophilic to brown granules in
the cytoplasm; and the presence of other microscopic
pathologic ﬁndings in the remaining tissues.
Immunophenotypic analysis was performed in all cases
with suitable material by a standardized Envision
TM
method employing 4 lm-thick, formalin ﬁxed, parafﬁn
embedded sections. Table 3 documents the pertinent,
Table 1 Synonyms that have been used for ceruminous neoplasms of
the external auditory canal [5–16]
Ceruminoma (ceruminomata)
Hidroadenoma
Adenoid cystic carcinoma
Adenocarcinoma of ceruminal type
Mucoepidermoid carcinoma
Syringocystadenoma papilliferum
Pleomorphic adenoma
Ceruminal adenoma
Mixed tumor of skin
Ceruminous adenoma
Cylindroma
Adenoma ceruminalis
Myoepithelioma
Clear cell carcinoma
Aural hidradenoma
Chondroid syringoma
Eccrine cylindroma (cutaneous eccrine cylindroma)
Cylindromatous lymphangioma
Cylindromatous deep hidradenoma
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panel used. The analysis was performed on a single rep-
resentative block for each primary tumor. When required,
proteolytic antigen retrieval was performed by predigestion
for 3 min with 0.05% Protease VIII (Sigma Chemical Co.,
St. Louis, MO) in a 0.1 M phosphate buffer, pH of 7.8, at
Table 2 Review of the English
literature on ceruminal
adenocarcinoma [4, 5, 10, 12,
14, 16–18, 29–32, 38–66]
a
a This table does not include
the series reported in this study
b Parameter was not stated in
all cases
c Patients may have
experienced more than one
symptom
Characteristics Ceruminous carcinoma
Total: N = 91
Gender
Women 54
Men 37
Age (in years)
Range 21–92
Mean 49.0
Women (mean) 49.7
Men (mean) 48.0
Symptom duration (in months)
b
Range 1–444
Mean 51.6
Women (mean) 41.7
Men (mean) 64.4
Symptoms at presentation
b,c
Pain (otalgia) 48
Mass 34
Hearing changes (loss, tinnitus) 33
Drainage, discharge, bleeding 31
Nerve changes (paralysis, paresthesias) 7
Location (n = 72)
b
Left 39
Right 33
Size (in cm)
b
Range 0.5–3.0
Mean 1.41
Median 1.3
Tumor histology:
Adenoid cystic carcinoma 64
Adenocarcinoma, ceruminous 22
Mucoepidermoid carcinoma 4
Sebaceous carcinoma 1
All patients with follow-up (n = 81) (months) 83.9 (mean)
Follow-up range 1–348
Alive, no evidence of disease (n = 37) 68.6 (5.7 years)
Alive, with disease (n = 13) 108.5 (9.0 years)
Dead, no evidence of disease (n = 6) 154.0 (12.8 years)
Dead, with disease (n = 25) 77.0 (6.4 years)
Alive/Dead, no evidence of disease (n = 43) 80.5 (6.7 years)
Alive/Dead, with disease (n = 38) 87.7 (7.3 years)
Patient outcome by tumor histology:
b
Adenocarcinoma, ceruminous
b (n = 20) 55.9 (4.7 years)
Adenoid cystic carcinoma
b (n = 56) 99.8 (8.3 years)
Mucoepidermoid carcinoma
b (n = 4) 18.5 (1.5 years)
Patient outcome for patients with recurrence (n = 49) 102.6 (8.5 years)
Patient outcome for patients without recurrence (n = 32) 55.3 (4.6 years)
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required, by using formalin-ﬁxed, parafﬁn-embedded tissue
treated with a buffered citric acid solution pH 6.0 (Citra,
Dako Corporation, Carpinteria, CA) and heated for 20 min
in a steamer. Following this, the sections were allowed to
cool at room temperature in a citric acid buffer solution for
45 min before continuing the procedure. Standard positive
controls were used throughout, with serum used as the
negative control. The antibody reactions were graded as
absent to weak (0 to 1?), moderate (2? to 3?) and strong
(4?) staining, and the fraction of positive cells was
determined by separating them into four groups: \10%,
11–50%, 51–90%, and [90%, especially for the prolifer-
ation markers.
A review of publications in English (MEDLINE 1966–
2008) was performed, with all cases reported as ceruminal
neoplasms included in the review. However, many cases
were excluded if the lesion arose primarily in the middle
ear, endolymphatic sac region, or represented a neuroen-
docrine adenoma (middle ear adenoma), or a primary
salivary gland (parotid) tumor or extended into the ear from
a tumor ‘‘centered’’ in the oral cavity, nasal cavity, naso-
pharynx, sinuses, or soft tissues of the neck were excluded
[2, 8, 15, 19–28].
Results
Clinical
The patients included 6 women and 11 men (Table 4).
Their ages ranged from 33 to 82 years of age, with an
overall mean age at presentation of 59.5 year (median,
Table 3 Immunohistochemical panel
Antigen/antibody Primary
antibody
Company Dilution Cellular conditioning
Cytokeratin
(AE1/AE3 and LP34)
mm Boehringer Mannheim Biochemicals,
Indianapolis, IN, and Dako, Carpinteria, CA
1:50
Protease digestion
1:200
Epithelial membrane antigen (EMA) mm Ventana, Tucson, AZ Neat Protease digestion
CK7 mm Dako 1:400 Protease digestion
CK5/6 mm Dako 1:20 Steam
CK20 mm Dako 1:200 none
S-100 protein rp Dako 1:800 none
CD117 mm Dako 1:100 Steam
p53 mm Dako 1:2400 Steam
p63 mm Novocastra, Newcastle-upon-Tyne,
United Kingdom
1:100 Steam
Ki67 mm Immunotech, Westbrook, ME 1:20 Steam
mm mouse monoclonal; rp rabbit polyclonal
Table 4 Clinical and macroscopic characteristics
Clinical characteristics Ceruminous carcinoma
Gender
Women 6
Men 11
Age (in years)
Range 33–82
Mean 59.5
Women (mean) 56.2
Men (mean) 61.3
Symptom duration (in months)
Range 2.5–24
Mean 8.2
Women (mean) 18.0
Men (mean) 6.3
Symptoms at presentation
a
Mass 14
Hearing changes 5
Drainage 4
Pain 2
Nerve changes (paralysis) 3
Location
Left 7
Right 10
Size (in cm)
Range 0.5–3.0
Mean 1.8
Women (mean) 1.4
Men (mean) 2.0
a Patients may have presented with more than one symptom; there-
fore the numbers do not add up to the total number of patients
4 Head and Neck Pathol (2009) 3:1–1764 years). The average age at presentation for women was
younger than men, at 56.2 and 61.3 years, respectively, but
there are too few cases to reach statistical signiﬁcance.
Patients most frequently presented with a mass lesion in the
outer one-half of the external auditory canal (n = 14).
Other symptoms included hearing changes usually con-
ductive rather than sensorineural (n = 5), otitis with
drainage (n = 4), pain (n = 2), and nerve changes or
paralysis (facial nerve or other cranial nerve involvement;
n = 3). Most patients presented with more than one
symptom while there were no asymptomatic patients. By
deﬁnition none of the tumors were centered in the parotid
gland or developed in patients who had a previous parotid
gland tumor, nor in patients who had a nasopharynx pri-
mary which had involved the eustachian tube. The duration
of symptoms ranged from 2.5 to 24 months, with an
average of 8.2 months. On average, women (mean,
18.0 months) experienced a longer duration of symptoms
than men (mean, 6.3 months), a ﬁnding without an obvious
explanation. When separated by histologic type, the mean
duration of symptoms was quite different: ceruminous
adenocarcinoma, NOS: 5.8 months; ceruminous adenoid
cystic carcinoma: 9.3 months; ceruminous mucoepider-
moid carcinoma: 24 months. Given the very limited
number of cases, statistical analysis could not conﬁrm these
differences.
Pathologic Features
Macroscopic
All neoplasms arose in the external auditory canal lateral to
the bony-cartilaginous junction, even though there was
extension into the mastoid bone, middle ear and base of the
skull in two patients. Tumors, when described, were
identiﬁed in the posterior–superior quadrant (n = 8). All
tumors were unilateral and the majority affected the right
side (n = 10; Table 4). The tumors were often exophytic,
ranged in size from 0.5 to 3.0 cm, with a mean size of
1.8 cm. The tumors which arose in women were smaller
(mean, 1.4 cm) than their male counterparts (mean,
2.0 cm), a curious ﬁnding given the inverse differences in
duration of symptoms (see above). There was a slight
difference in size of the tumor when separated by histo-
logic sub-type: ceruminous adenocarcinoma, NOS: 1.7 cm;
ceruminous adenoid cystic carcinoma: 1.6 cm; ceruminous
mucoepidermoid carcinoma: 3.0 cm. Axiomatic, the
tumors which extended into other parts of the ear, were
also larger (mean, 3.0 cm). Curiously, tumors on the left
were larger than those on the right (mean, 2.0 vs. 1.6 cm,
respectively). As a result of surgical procedures, the tumors
were received by the pathologist fragmented into small
pieces without an obvious surface epithelium. The tumor
samples were ﬁrm and grayish white to pink. It was
important to obtain an accurate location of the biopsy from
the surgeon, to exclude glandular neoplasms from the
parotid gland or middle ear.
Microscopic
The neoplasms do not have a true capsule and are not
circumscribed, but instead tend to inﬁltrate into the sur-
rounding stroma and bone (Fig. 1). Surface involvement
was identiﬁed in an only six cases (Fig. 2), with surface
ulceration in an additional neoplasm. The neoplasms were
divided into three major groups based on speciﬁc histologic
Fig. 1 Ceruminous adenoid cystic carcinoma. The surface is intact
(upper left). The neoplasm is arranged in glands, nests, cribriform and
solid groups inﬁltrating deep below the surface
Fig. 2 Ceruminous adenocarcinoma, NOS. An intact surface epithe-
lium is subtended by an inﬁltrating ‘‘biphasic’’ neoplastic
proliferation separated by dense ﬁbrosis
Head and Neck Pathol (2009) 3:1–17 5ﬁndings: ceruminous adenocarcinoma, not otherwise
speciﬁed (NOS) [n = 12], ceruminous adenoid cystic car-
cinoma [n = 4], and ceruminous mucoepidermoid
carcinoma [n = 1].
The ceruminous adenocarcinomas contained neoplastic
cells which were arranged in a variety of different patterns
within a single case as well as between cases (Table 5;
Fig. 3). Whereas a glandular pattern predominated in most
lesions (n = 15; Fig. 4), a ‘‘Swiss-cheese’’ or ‘‘cribriform’’
architecture is usually seen in ceruminous adenoid cystic
carcinoma (Fig. 5). The lesional cells invaded into the
surrounding stroma, a feature helpful in separating between
ceruminous adenomas and carcinoma. At least focally, a
dual cell population could always be identiﬁed, comprised
of inner luminal epithelial cells subtended by basal/myo-
epithelial cells adjacent to the basement membrane
(Figs. 6, 7). In the adenoid cystic carcinoma, the cells were
‘‘peg’’ or ‘‘carrot-shaped’’ with scant cytoplasm surround-
ing hyperchromatic nuclei (Fig. 8). When the luminal cells
were identiﬁed, prominent apical caps with ceruminous-
type decapitation secretion (n = 5) were displayed. The
golden-yellow-brown pigment granules were not seen in
this type of ceruminous adenocarcinoma. The tumors
tended to have a moderate to high cellularity composed of
cells with variably degrees of nuclear pleomorphism.
Nucleoli were often prominent. Mitotic ﬁgures were usu-
ally easy to identify, with occasional atypical forms. Tumor
necrosis (not degenerative change) was not observed in
adenoid cystic carcinoma, but could be seen in ceruminous
adenocarcinoma, NOS (Fig. 9). Inﬂammatory cells and
areas of dense hyalinization (sclerosis) were seen. Muco-
epidermoid carcinoma contained epidermoid cells, mucin-
producing cells, and transitional cells, associated with focal
apocrine snouts, conﬁrming ceruminous derivation
(Fig. 10).
Table 5 Microscopic features
Feature Ceruminous carcinoma
Growth pattern
Glandular 15
Inﬁltrating 12
Solid 8
Cystic 8
Dual population 15
Surface involvement 6
Ulceration 1
Mitotic ﬁgures (mean per 10 HPF) 2.9
Atypical mitotic ﬁgures present 6
Pleomorphism
Mild 3
Moderate 10
Severe 4
Cellularity
Low 1
Moderate 7
High 9
Prominent nucleoli 13
Ceruminal apocrine decapitation secretion 14
Necrosis present 2
Cerumen/wax granules 0
Associated ﬁndings:
Cholesteatoma 1
HPF High power ﬁeld
Fig. 3 Ceruminous adenocarcinoma, NOS. Glands, papillary struc-
tures, and tubules inﬁltrate into a heavily desmoplastic stroma. Note
apoptosis and focal comedotype necrosis
Fig. 4 Ceruminous adenocarcinoma, NOS. Hyperchromatic and
moderately pleomorphic cells demonstrating a dual cell layer. The
inner, more eosinophilic cells, are apocrine cells with focal decap-
itation secretions, while the outer layer is composed of myoepithelial
cells
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All lesions tested reacted strongly and diffusely with a
keratin cocktail and with epithelial membrane antigen
(Table 6). Where the surface epithelium was present, it was
strongly and diffusely immunoreactive for the epithelial
markers analyzed, and served as an internal quality control.
The dual cell population was accentuated by the immu-
nohistochemical studies. The luminal cells were strongly
immunoreactive with CK7 and with CD117 (Fig. 11). The
basal-myoepithelial cells were strongly and diffusely
reactive in both the nucleus and cytoplasm with S-100
protein (63%), in the cytoplasm with CK5/6 (50%) and in
the nucleus only with p63 (38%; Fig. 12). Thirty-seven
percent of cases tested demonstrated Ki-67 immunoreac-
tivity ranging from 2? to 3?, affecting greater than 5% of
the nuclei in the specimen, while the others showed\1%
reactivity. p53 was identiﬁed in 57% of cases; although
immunoreactivity ranged from 1? to 3?, less than 10% of
the nuclei in the specimen were affected in 3 cases, while 1
case demonstrated reactivity in about 30% of nuclei. CK20
was negative in all cases tested.
Fig. 6 Ceruminous adenocarcinoma, NOS. The neoplastic cells are
atypical, demonstrating a dual cell population (inner and outer cell
layers)
Fig. 7 Ceruminous adenocarcinoma, NOS. Irregular glands sepa-
rated by desmoplastic stroma. Note the biphasic appearance with
inner cells subtended by myoepithelial cells. The degree of pleomor-
phism is severe in this case
Fig. 5 Ceruminous adenoid cystic carcinoma. The overall cribriform
(‘‘Swiss-cheese’’) pattern is seen on both the low power and within
the inset
Fig. 8 Ceruminous adenoid cystic carcinoma. The lower aspect
contains uninvolved ceruminous glands with small slightly yellow
ceroid granules in the cytoplasm. Note the ‘‘basaloid’’ cells
surrounding brightly eosinophilic luminal cells in the center of the
tumor nests, a feature of ceruminous differentiation
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All patients were treated by partial or complete surgical
excision; complete surgical removal of the tumor was
frequently impossible as a result of the complex anatomy
of the ear and temporal bone. No patients received adjuvant
chemotherapy, but four patients received radiation therapy
from 28 to 30 centigray. Follow-up data was obtained in all
17 patients (Table 7). There was an overall 8.9 year mean
follow-up. Eleven patients were either alive (n = 8) or had
died (n = 3) without evidence of disease at last follow-up,
an average of 11.2 years after diagnosis. Six patients had
died of disease, an average of 4.9 years after initial pre-
sentation. Of the patients who died, three had widely
Fig. 10 Ceruminous mucoepidermoid carcinoma. Intermediate, epi-
thelial cells and mucous cells are readily identiﬁed in this inﬁltrating
neoplasm
Fig. 9 Remarkably atypical epithelial cells are seen surrounding an
area of central comedonecrosis, an uncommon feature in ceruminous
gland adenocarcinomas
Table 6 Immunohistochemical panel results
Antibody Number of cases
with positive reactions
Cytokeratin (AE1/AE3 and LP34) 8/8 (100%)
Epithelial membrane antigen (EMA) 8/8 (100%)
CK7 (luminal only) 6/8 (75%)
CK5/6 (basal cells predominantly) 4/8 (50%)
CK20 0/8 (0%)
S-100 protein (basal cell only) 5/8 (63%)
CD117 3/8 (38%)
p53 4/7 (57%)
p63 3/8 (38%)
Ki67 3/8 ([5% reactivity)
Fig. 11 Ceruminous adenocarcinoma, NOS. Note the strong reaction
with CD117 in the tumor cells
Fig. 12 Ceruminous adenocarcinoma, NOS demonstrates a ‘‘bi-
phasic’’ immunoreactivity with the outer cell layer demonstrating a
positive CK5/6 and p63 immunoreactivity. The Ki-67 demonstrated
increased reactivity in some adenocarcinomas
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had local recurrence (mean survival, 3.0 years). The local
recurrence involved extension into the base of the skull or
brain which resulted in the patient’s death. The locally
recurrent tumors were histologically identical to the
primaries, without de-differentiation. None of the patients
in this series developed lymph node metastases. The three
patients with metastatic disease all developed locally
recurrent disease ﬁrst, associated with inﬁltration of the
base of the skull, with further development of lung
metastases. One of these patient’s also developed liver
metastases. The liver metastasis was histologically similar
to the primary mucoepidermoid carcinoma. Of the patients
who died of their disease, there were three with ceruminous
adenocarcinoma, NOS (mean survival, 2.0 years), two with
ceruminous adenoid cystic carcinoma (mean survival,
10.0 years), and one with ceruminous mucoepidermoid
carcinoma (survival, 3.1 years). The four patients who
received radiation therapy had an overall mean follow-up
of 9.3 years; two patients died with disease (mean,
4.2 years), and two patients were alive with no evidence of
disease at last follow-up (mean, 14.3 years). One of the
patients who received radiation had a ceruminous muco-
epidermoid carcinoma (3.1 years), while the other three
had ceruminous adenocarcinoma, NOS (mean follow-up,
11.3 years). Six of the patients developed recurrences,
although one patient developed ‘‘recurrence’’ and died with
disease in 0.3 years. This patient was interpreted to have
residual disease, incompletely excised at the ﬁrst surgery,
with extension into the skull and base of brain (ceruminous
adenocarcinoma, NOS). The remaining ﬁve patients who
developed recurrences were all managed with extensive
local resection (including temporal bone resection), with
two of these patients also undergoing adjuvant radiation
therapy. The recurrences developed in three patients with
ceruminous adenocarcinoma, NOS (mean survival,
8.3 years), two patients with adenoid cystic carcinoma
(mean survival, 10.0 years), and one patient with muco-
epidermoid carcinoma (survived, 3.1 years). The
recurrences developed within a few months to 4.1 years
after the primary tumor diagnosis. There is no statistically
signiﬁcant difference in overall survival between patients
who developed a recurrence and those who did not. Fur-
ther, there was no statistically signiﬁcant difference in
outcome between men and women, or between the differ-
ent tumor types. However, while patients with ceruminous
adenocarcinoma, NOS tend to have an overall shorter
survival (mean, 9.1 years) than patients with adenoid cystic
carcinoma (mean, 9.9 years), the number of cases was
insufﬁcient to reach statistical signiﬁcance.
Discussion
The normal external ear canal is an S-shaped passage
measuring about 2.5 cm, lined by a very thin squamous
mucosa covering scant ﬁbrous stroma containing both
sebaceous and modiﬁed apocrine sweat glands—ceruminal
glands [29–31]. Hair follicles develop by invagination from
the epidermis with sebaceous glands and ceruminous
glands branching from the epithelium lining follicular root
sheaths, together forming the apopilosebaceous unit [32].
The ceruminal glands are deep within the dermis, usually
bordering the cartilage which is present in the outer one-
third to one half of the canal. The inner bony portion of the
canal does not contain ceruminal glands. The external
auditory canal is bounded anteriorly by the temporoman-
dibular joint, inferiorly by the parotid space and posteriorly
by the mastoid air cells [29]. The ceruminal glands are
comprised of columnar cells containing intensely eosino-
philic cytoplasm, frequently displaying ‘‘apical caps,’’
‘‘secretory snouts,’’ or ‘‘blebbing.’’ These cells are sur-
rounded by a layer of myoepithelial cells. By deﬁnition,
ceruminous cells lose part of their cytoplasm during
secretion, different from the holocrine sebaceous glands,
which lose all of the cell as part of the secretion. Ceruminal
glands are typical apocrine sweat-glands with a watery
ﬂuid secretion devoid of lipids. This ﬂuid drains into ducts
which open, along with the sebaceous gland ducts, into the
hair sacs of the ﬁne hairs in the ear canal. This ﬂuid mixes
Table 7 Patient outcome for 17
ceruminous carcinomas (mean
years of follow-up)
A, NED Alive, no evidence of
disease; D, NED Dead, no
evidence of disease; D, D Dead,
with disease; n/a Not
applicable; NOS Not otherwise
speciﬁed
All patients A, NED D, NED D, D
All patients with follow-up 17 (8.9) 8 (12.0) 3 (8.8) 6 (4.9)
Follow-up range 0.4–21.6 3.4–21.6 2.5–12.9 0.3–11.6
Patients with recurrence 6 (8.0) 1 (19.2) n/a 5 (5.7)
Men 11 (8.2) 3 (12.5) 3 (8.8) 5 (5.2)
Women 6 (10.4) 5 (11.8) n/a 1 (3.1)
Tumor histology:
Adenocarcinoma, NOS 12 (9.1) 7 (12.8) 2 (6.7) 3 (2.0)
Adenoid cystic carcinoma 4 (9.9) 1 (6.9) 1 (12.9) 2 (10.0)
Mucoepidermoid carcinoma 1 (3.1) n/a n/a 1 (3.1)
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cerumen (wax, ceroid). The luminal secretory cells contain
cytoplasmic golden yellow-brown, water-insoluble lipo-
protein pigment granules, similar to apocrine glands
elsewhere, although these pigment granules do not become
part of the secretion (Fig. 8)[ 8, 10, 29–31, 33]. These
granules are periodic acid-Schiff (PAS) positive, Sudan
black positive, and also stain with the Ziehl-Neelsen acid-
fast method. It is quite interesting to note that while this
yellow-brown granule conﬁrms the ceruminous nature of
the benign neoplasms (ceruminous adenoma), these gran-
ules are not identiﬁed in the cytoplasm of the malignant
neoplasms [30]. The immediately adjacent, uninvolved
ceruminous glands will contain the pigment, helping to
conﬁrm the point of origin, and this ﬁnding can be helpful
when trying to separate benign and malignant neoplasms of
the ceruminous glands, especially when the biopsies are
small and limited. Many ceruminous neoplasms contain
both epithelium and myoepithelium, helping to conﬁrm an
origin of these tumors from ceruminous glands [10, 34, 35].
There has been a view that ectopic salivary gland within
the ear canal may be the source of tumor. However, sali-
vary gland tissue, the lining of the middle ear, and
eustachian tube are derived from the expanding terminal
end of the ﬁrst pharyngeal pouch, different from the epi-
thelium of the external auditory canal. Sebaceous glands in
the external auditory canal may be a potential site of origin
for ceruminous mucoepidermoid carcinoma, but as these
glands are intimately associated with the ceruminal glands
(secretions blend to create cerumen), this possibility cannot
be conﬁrmed.
Nomenclature
Reviewing the literature relevant to tumors of the ceru-
minous gland region is burdened with a multitude of
problems. These difﬁculties include confusion about the
terms which have been applied to ceruminous tumors,
inadequate histologic descriptions, and a lack of pertinent
illustrations (Table 1). Speciﬁcally, over the past few
years, diagnostic terms have been applied more rigorously
to tumors, allowing for the more accurate separation of
tumors. The endolymphatic sac tumor [36], neuroendocrine
adenoma of the middle ear [37], middle ear adenocarci-
noma, and ceruminous adenoma [35] have been much more
completely described and reﬁned. Critical review of many
of the earlier case reports of ceruminous neoplasms allow
for a more accurate placement in different tumor categories
[2, 8, 15, 19–28]. Careful review of the remaining cases,
most of which are single case reports or limited case series,
further narrows the number of cases available for review
(see Table 2)[ 4, 5, 10, 12, 14, 16–18, 29–32, 38–66].
Ceruminous tumors are so uncommon that only the
experience which can be achieved from a referral center or
academic medical center would allow for an improve-
ment in the understanding of this neoplastic category.
Advancement in understanding ceruminous neoplasms can
be made by the strict application of more uniform
nomenclature. While it is not the foremost purpose of this
study to resolve taxonomic issues nor to speciﬁcally cor-
rect nosological preferences, a considerable part of the
confusion attending this group of neoplasms can be
attributed to the persistent use of inappropriate terms.
Therefore, comment must be made to assist the pathologist
and clinician alike in implementing uniform nomenclature
(Table 8).
Malignancies of the ceruminous glands of the external
auditory canal constitute a rather uncommon group of
tumors, representing\0.0001% of all surgical cases stud-
ied [4]. The generic ‘‘ceruminoma’’ and ‘‘cylindroma’’ has
been used to encompass both histologically benign and
malignant glandular tumors of the external auditory canal,
thereby providing the clinician and surgeon with little
value and no guidance as to management and follow-up.
The continued use of these names, particularly ceruminoma
and cylindroma, is strongly discouraged and are viewed as
‘‘defunct’’ [4, 10, 17, 19, 31, 34, 35, 67]. The tumors are
correctly classiﬁed under benign and malignant categories.
The benign category encompasses ceruminous adenoma,
ceruminous pleomorphic adenoma and ceruminous syrin-
gocystadenoma papilliferum. The malignant category
includes ceruminous adenocarcinoma, not otherwise spec-
iﬁed (NOS), ceruminous adenoid cystic carcinoma and
ceruminous mucoepidermoid carcinoma, each deﬁned by
the unique attributes of the underlying malignancy. With
this terminology in mind, a comparison of the cases
reported in the literature to the cases in this study is carried
out.
Clinical
All of the neoplasms studied in our series and in those of
the literature developed exclusively in adults, with this
study’s age range of 33–82 years, encompassed by the
Table 8 Nomenclature for ceruminous (ceruminal) neoplasms of the
external auditory canal
Benign neoplasm Malignant neoplasm
Ceruminous adenoma Ceruminous adenocarcinoma, NOS
Ceruminous pleomorphic
adenoma
Ceruminous adenoid cystic
carcinoma
Ceruminous
syringocystadenoma
papilliferum
Ceruminous mucoepidermoid
carcinoma
NOS Not otherwise speciﬁed
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sentation [4, 17, 18, 31]. Malignant neoplasms tend to
develop at a younger age at initial presentation than benign
neoplasms, a difference of approximately one decade,
although it is difﬁcult to achieve statistical signiﬁcance
with this type of meta analysis [4, 18, 35]. There was no
statistical difference in the age at presentation between men
and women, either for our study or for the average age at
presentation for those patients reported in the literature.
There is a slight gender predilection for female patients
when the patients in this series are combined with those in
the literature (F:M = 5:4). The greater number of men in
this clinical series may be biased by cases from military
and Veterans Administration hospitals which tend to be
male dominant. Gender did not seem to inﬂuence tumor
type, as the most common tumor type identiﬁed in either
gender was ceruminous adenoid cystic carcinoma (women,
74%; men, 65%). However, in this clinical series, ceru-
minous adenocarcinoma, NOS was the most common
tumor type, perhaps due to a selection bias of a consulta-
tion service, where ceruminous adenocarcinoma, NOS may
be more difﬁcult to diagnose than a ceruminous adenoid
cystic carcinoma.
The most common symptoms reported in the literature
and in our patients included pain (otalgia), mass, and
hearing changes (hearing loss, deafness, tinnitus, popping).
Other symptoms included drainage, discharge, infection,
bleeding, paralysis, paresthesias, weakness, syncope, diz-
ziness, equilibrium changes, headaches, swelling, drum
perforation, and visual changes [4, 10, 17, 18, 29, 53]. No
patients in our series were asymptomatic, but asymptom-
atic patients have been reported [50]. Symptoms did not
speciﬁcally correlate with a distinct tumor type, with
duration of symptoms, nor with patient outcome. Some in
the literature have suggested that patients with a long
symptom duration tend to have a worse outcome [68], but
we were unable to conﬁrm this result nor tease this infor-
mation from the reported cases. In this clinical series, the
duration of symptoms ranges from 2.5 months to 2 years,
with the mean being 8.2 months. This average is signiﬁ-
cantly shorter than the mean reported in the literature
(51.6 months). The potential reasons for this remarkable
discrepancy are: (1) cases reported in the literature do not
give length of symptom duration (29 cases have no infor-
mation); (2) there tends to be a reporting bias towards the
unusual or uncommon, such as with patients who have had
symptoms for greater than 10 years [4, 29, 31, 64]; (3) the
median in the literature is 27.5 months, a much more
realistic symptom duration than the mean 51.6 month. Our
analysis shows an interesting breakdown along gender.
Women presented having symptoms an average of one year
longer (18 months) in duration then men (6.3 months), but
this may just be due to the limited number of cases, as the
difference between men and women reported in the liter-
ature is the exact opposite (men: 64.4 months; women:
41.7 months).
Pathology Features
On physical exam, the masses ranged in size from 0.5 to
3.0 cm, identical to those the cases reported in the litera-
ture. The mean size of 1.8 cm is slightly larger than those
reported in the literature (mean, 1.4 cm). It is important to
note, small biopsies may lead to incorrect interpretation.
Therefore, caution is advised when only isolated fragments
of tumor are included in the sample. Interestingly, in this
clinical study even though the female patients tended to
suffer with symptoms for a longer duration, their tumors
were on average were over a half a centimeter smaller than
their male counterparts (females: mean, 1.4 cm; males:
mean, 2.0 cm). The female patient’s mean tumor size
reported in the literature is quite similar at 1.5 cm, although
the mean size reported for males was smaller than our
patients, at 1.2 cm. We do not have an explanation for the
size differences. Although the tumors in this study affected
the right side (n = 10) more frequently than the left
(n = 7), there was no statistically signiﬁcant difference, a
ﬁnding similar to the patients reported in the literature
(left = 39; right = 33).
Based on the well established criteria for adenoid cystic
carcinoma and mucoepidermoid carcinoma in other ana-
tomic sites, the tumors in this series were separated into
ceruminous adenocarcinoma, NOS (n = 12), ceruminous
adenoid cystic carcinoma (n = 4), and ceruminous muco-
epidermoid carcinoma (n = 1). Axiomatic but still
important, these tumors arose primarily in the external
auditory canal without any direct continuity with the adja-
cent salivary gland; parotid gland speciﬁcally. It is well
known that salivary gland primaries may invade along
nerves and be identiﬁed synchronously or metachronously
in the external auditory canal, sometimes many years after
the primary parotid gland tumor was removed [4]. Further,
there may have been extension into the middle ear via
erosion of the tympanic membrane, but no tumors were
centered within the middle ear and/or eustachian tube. The
latter would be considered as a separate group of neoplasms
and are not considered ceruminous primaries. As previously
stated, the larger proportion of ceruminous adenocarci-
noma, NOS cases may reﬂect the bias of a consulting
service. It could be argued that ceruminous adenocarci-
noma, NOS may be more difﬁcult to diagnosis than either
mucoepidermoid carcinoma or adenoid cystic carcinoma,
and therefore we may see more of the former. Overlap
between histologic categories is inevitable, but emphasis is
given to the dominant pattern. Therefore, while we iden-
tiﬁed some adenocarcinomas that had focal features of
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tures were present to warrant this diagnosis.
A peculiar ﬁnding is an overall greater number of
malignant tumors of ceruminous glands than benign
tumors; it is uncertain whether this may be in part of a
reporting bias [4, 11, 17, 18, 29, 31, 34, 35]. If limited to
the cases at the Armed Forces Institute of Pathology,
malignant tumors were not as common as benign tumors—
but this may be due to a selection bias of cases [35].
Malignant-appearing cases are more likely to be sent for
consultation, with a change in the diagnosis to a benign
lesion altering the number of reported cases. This inference
requires further evaluation to draw a deﬁnitive conclusion.
Irrespective of the tumor type, all were inﬁltrative
neoplasms, without a capsule, showing extension into the
native ceruminous glands, adipose tissue and even temporal
bone. Inﬁltration is a helpful feature when trying to separate
benign from malignant ceruminous neoplasms, although
benign tumors tend to have a hyalinized ﬁbrosis which
creates a ‘‘pseudoinﬁltrative’’ pattern [35, 69]. Many times
the samples are small and fragmented. Therefore, while
inﬁltration can be helpful, it is not as useful in an individual
case as suggested by the ﬁndings in this series and the liter-
ature. Interestingly, perineural invasion and lymph-vascular
invasionisdifﬁculttodetect[31].Whenpresent,however,it
helps to deﬁne the malignant nature of the tumor.
Histologically, the ceruminous glands lie ‘‘deep’’ in the
dermis in propinquity to cartilage, not at the surface [29].
However, ceruminous glands disgorge their secretions via
ducts onto the surface. The skin in the outer two-thirds of
the ear canal is only about 0.2 mm thick, suggesting that
even though ‘‘deep’’ in the dermis, they are still relatively
close to the surface [29]. Therefore, it is not uncommon to
ﬁnd ceruminous neoplasms extending to the surface epi-
thelium, as noted in six of our cases. This ﬁnding does not
support a surface origin, however, only a surface involve-
ment. Moreover, Pagetoid spread within the epidermis was
not identiﬁed. Ulceration was seen in only a single case in
this clinical series, and shown in a few of the reported cases
in the literature. Then again, surface ulceration can be seen
in benign tumors, making ulceration alone less speciﬁc for
malignancy. Further, the ear canal is a small, conﬁned
space, frequently subjected to trauma (cotton tipped
applicators, digital exam), which may result in ulceration
unrelated to the underlying disease.
Ceruminous adenocarcinomas, NOS are similar to ade-
nocarcinomas of any anatomic site, except that ceruminous
glands are identiﬁed adjacent to or within the tumor.
Tumors show an increased cellularity, with cells demon-
strating anisocytosis and pleomorphism. The cells
generally resemble secretory cells, although demonstrating
back-to-back gland formation and irregular glandular
conﬁgurations [31]. Papillary structures can be seen,
although they are seldom dominant [45]. Nucleoli are
easily identiﬁed in approximately 75% of cases. Prominent
nucleoli may be a helpful feature, since benign neoplasms
tend not to have prominent nucleoli [35]. Decapitation
secretions or prominent apical caps were seen in over 80%
of cases, even when the tumors were poorly differentiated,
another support for ceruminous origin. This ﬁnding is
different from other authors who failed to identify apocrine
blebs in poorly differentiated tumors [18]. The secretions
were frequently admixed with cellular debris within the
gland lumen. The characteristic golden-yellow-brown
pigment (cerumen granules) within the cytoplasm of
benign ceruminous glands and benign ceruminous neo-
plasms, is not identiﬁed in malignant tumors [30]. This
absence (after careful examination) may help in separating
benign from malignant ceruminous tumors. Myoepithelial
cells, the basal layer of normal ceruminous glands, were
easily identiﬁed in most tumors, although much more
easily accentuated with immunohistochemical myoepithe-
lial and basal markers (S-100 protein, p63). These cells
often show a cleared cytoplasm, creating a ‘‘light’’ cell
immediately adjacent to the ‘‘dark’’ cell of the ductal or
luminal cell.
Mitotic ﬁgures are usually easy to ﬁnd although the
overall mean was 2.9 ﬁgures per 10 high power ﬁelds.
Some of the tumors had no mitotic ﬁgures. Therefore,
increased mitotic ﬁgures may assist in the diagnosis of
malignancy, but a lack of mitotic ﬁgures does not exclude a
caricnoma [35]. In fact, ceruminous adenoid cystic carci-
nomas generally lack mitoses, and overall, this is the most
common tumor type in the meta analysis. Atypical mitotic
ﬁgures are not identiﬁed in benign tumors and were present
in 35% of cases in this series. Hence, atypical mitotic
ﬁgures may aid in making a malignant diagnosis, but their
absence does not rule out carcinoma.
Ceruminous adenocarcinoma, NOS infrequently con-
tained tumor necrosis (n = 2), but when present, was
considered diagnostic of carcinoma. Likewise, perineural
invasion, when present (n = 1) was also considered diag-
nostic of carcinoma. Perineural invasion was only
identiﬁed in ceruminous adenocarcinoma, NOS, a curious
ﬁnding given the known proclivity for perineural invasion
in adenoid cystic carcinomas. This is different from the
frequently reported ﬁnding of perineural invasion in ceru-
minous adenoid cystic carcinomas [4, 10, 14, 17, 68].
These authors identiﬁed an increased risk of recurrence
when perineural invasion was identiﬁed. However, parotid
gland tumor extension (versus primary) cases were inclu-
ded, making this conclusion suspect.
Glandular differentiation was present in some form or
another in all tumors studied. Solid and cystic patterns
were seen about equally. Dual cell differentiation, one of
the key features of ceruminous gland neoplasms, was found
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show a dual cell layering was the ceruminous mucoepi-
dermoid carcinoma. Dual cell differentiation refers
primarily to the inner cuboidal and outer basal-myoepi-
thelial type cell, a ﬁnding seen in ceruminous glands.
Adenoid cystic carcinoma also shows this biphasic
appearance, but the decapitation secretions within the small
glands or within the tumor proper help to conﬁrm the dual
differentiation.
Adenoid cystic carcinoma is the most commonly
reported primary ceruminous gland malignancy, by a 2:1
ratio (when the current cases are added to those reported in
the literature) [4, 10, 14, 17, 29, 53]. Ceruminous adenoid
cystic carcinomas show morphologic diversity, but cyto-
logic uniformity. Similar to their salivary gland
counterparts, ceruminous adenoid cystic carcinomas show
cribriform, tubular and solid patterns, although the former
two predominate and are usually intermingled in a jigsaw
puzzle type conﬁguration. The low power sieve-like, per-
forated, or Swiss cheese-like pattern is easily recognized,
and are probably the most useful initial feature in ceru-
minous tumor separation, as this pattern is not identiﬁed in
ceruminous adenocarcinoma, NOS nor in mucoepidermoid
carcinoma. The cylindrical, pseudocyst-like structures
contain abundant, brightly eosinophilic connective tissue
stroma and reduplicated basement membrane-lamina
material which surrounds the epithelial cells, and since it is
part of the stroma, is contiguous with it and meanders
throughout the background in a nearly continuous stream.
These structures are different from the isolated, true glan-
dular lumens which are lined by cuboidal ductal cells.
These small ductal areas are easy to miss in the over-
whelmingly predominant basaloid cell proliferation, but
identiﬁcation allows for accurate classiﬁcation. The basa-
loid-myoepithelial type cells are usually small with a high
nuclear to cytoplasmic ratio, indistinct cell borders, and a
nearly syncytial appearance. The nuclei are frequently
angular to ‘‘peg-shaped,’’ containing homogenous, darkly
basophilic chromatin. Nucleoli are usually inconspicuous.
The cytoplasm is lightly eosinophilic to clear, the latter
more prominent in myoepithelial-type cells. Mitotic ﬁgures
are difﬁcult to identify and necrosis is usually absent. The
appearance of decapitation-type apocrine snouts on some
of the luminal cells and the bilayered, eosinophilic neo-
plastic cells helps to conﬁrm a ceruminous origin for the
neoplasm.
Ceruminous mucoepidermoid carcinoma is the most
uncommon tumor type affecting the external auditory
canal. By deﬁnition, this tumor has mucous, epidermoid,
and transitional or intermediate cells, blended together,
although the intermediate cells tend to dominate. Cysts or
dilated ducts are usually present somewhere within the
tumor, frequently ﬁlled with mucinous material. The
epidermoid cells have ample to abundant eosinophilic to
clear cytoplasm, creating a polygonal appearance. Dys-
keratosis, keratin pearl formation, and intercellular bridges
are usually absent in this tumor. The intermediate cells tend
to have less cytoplasm than epidermoid cells, with a
slightly higher nuclear to cytoplasmic ratio and less
polygonal appearance. The nuclear chromatin is granular to
condensed, but not as condensed as in epidermoid cells.
Large, goblet shaped mucocytes contain abundant clear to
foamy cytoplasm which compress or indent the nucleus,
creating a signet-ring type appearance. These cells are
scattered throughout the neoplasm, occasionally arranged
in sheets or linear groups, and most commonly found lin-
ing cystic or duct-like spaces. These cells can be
highlighted with alcian blue or mucicarmine stains.
Interestingly, a clear cell morphology is not the dominant
ﬁnding in ceruminous mucoepidermoid carcinomas.
Background ﬁbrosis is a minor component, along with
scattered inﬂammatory cells.
One case was associated with a cholesteatoma. While
these two separate entities are perhaps unrelated, the
symptoms of the cholesteatoma may have brought attention
to the malignant ceruminous gland neoplasm earlier. It is
also possible, however, that the reverse is true. Choleste-
atoma is not discriminating, also documented in benign
ceruminous adenomas [35].
Immunohistochemistry may help to highlight the
biphasic appearance of ceruminous neoplasms, with lumi-
nal ductal and abluminal myoepithelial cells in both
ceruminous adenocarcinoma, NOS and ceruminous ade-
noid cystic carcinoma. First, all cases reacted with pan-
keratin. The CK7 was notable for selective reactivity in the
glandular luminal cells in 75% of the cases. The basal cell
layer, composed of myoepithelial cells, was reactive to
S-100 in 63% of the cases and p63 in all cases tested.
CD117 was reactive in neoplastic cell in 38% of the cases.
Ki67 was reactive at a rate of approximately 5% in 3 out of
the 8 cases that were analyzed. This indicates a modest
proliferation rate. These three tumors, however, were also
some of the larger tumors (average size of 2.1 cm) upon
presentation. Therefore, while immunohistochemistry aids
in highlighting the individual components of the neoplasm,
but it does not seem to aid in the diagnosis of ceruminous
malignancies based on currently available antibodies
studied.
Treatment and Outcome
Follow-up was available in all of the patients in this clin-
ical series. The overall prognosis is good, with an average
follow-up of 8.9 years for all patients. The patients who
died from their disease, had a mean time to death of
4.9 years from the time of initial presentation. However,
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NOS died of disease a mean of 2.0 years after presentation,
50% of patients with ceruminous adenoid cystic carcinoma
died of disease a mean of 10 years after initial presentation.
These ﬁndings are quite similar to the much longer survival
periods reported for patients with ceruminous adenoid
cystic carcinoma (mean, 8.3 years) than for ceruminous
adenocarcinoma, NOS (mean, 4.7 years). However, most
patients with adenoid cystic carcinoma had recurrences
develop, both in this series and in the patients reported in
the literature [4, 10, 18, 34, 68, 70]. If a recurrence
developed, there seems to be a much greater chance of
dying from disease (83%) versus patients who did not
develop a recurrence (9%) [4, 68]. Analysis of the cases in
the literature also suggests there is a longer overall survival
when a recurrence develops (mean, 8.5 years) versus no
recurrence (mean, 4.6 years). However, this is probably
related speciﬁcally to tumor type (ceruminous adenoid
cystic carcinoma), which tends to develop recurrences later
in the course of the disease, thereby resulting in a pro-
longed survival. In fact, it is not uncommon to develop
metastatic foci in the lung many years after the primary
tumor was identiﬁed [50]. Therefore, an initial extensive,
widest practical and meticulous excision, with close clini-
cal follow-up, especially in patients with adenoid cystic
carcinoma, may help to delay death from recurrent disease
or decrease the chance of recurrence. Surgeons may be
reluctant to perform ‘‘radical’’ surgery for tumors which
appear small, but given the very high tendency for local
recurrence and metastatic disease, this effort is warranted
and required. In fact, extended mastoidectomy, involved
dura, and total parotidectomy including mandibular con-
dyle may be required for ceruminous adenoid cystic
carcinoma to adequately control local disease.
Surgical margin positivity at initial surgery, bone
extension, perineural invasion and local recurrence seem to
be important prognostic factors for cases in the literature
[4, 10, 18, 34, 68, 70], but a number of these factors could
not be independently assessed in this study. However,
patients who had more aggressive surgical removal at or
immediately after initial presentation were less likely to
have recurrences, although independence from tumor his-
tology could not be determined. Along this same line, other
authors have included cases with parotid gland involve-
ment in their studies of primary ceruminous gland
neoplasms [4, 10, 14, 17, 18, 29, 31, 43, 53, 71, 72]. When
follow-up was performed, patients with parotid gland
involvement had [90% recurrence rates and often died
from their disease, as perhaps would be expected from
tumors which arose in the parotid gland and extended into
the bone and soft tissue of the external auditory canal.
Interestingly, when tumor type was stratiﬁed against
outcome, there was no statistically signiﬁcant difference in
patient outcome: ceruminous adenoid cystic carcinoma:
30.4% die of disease; ceruminous adenocarcinoma, NOS:
35% die of disease; mucoepidermoid carcinoma: 50% die
of disease (but with only 4 cases reported, statistical sig-
niﬁcant cannot be determined). Therefore, while there is a
longer overall survival for patients with ceruminous ade-
noid cystic carcinoma (mean, 8.3 years) versus ceruminous
adenocarcinoma, NOS (mean, 4.7 years), a similar per-
centage of patients die from disease in each category.
However, with improved surgical techniques, perhaps
additional surgery can help to secure a longer survival even
though it may not change the ultimate outcome. There is no
statistically signiﬁcant difference between males and
females, independent of tumor type: females: mean
7.6 years; males: mean, 6.1 years. Likewise, a similar
percent of men and women died from their tumors
(females: 30.6%; males 31.3%), although in this study a
greater number of men died of their disease (45%) versus
women (17%). This result may be due to consultation bias
rather than a true ﬁnding, as the large number of cases in
the literature suggest. Similarly, overall, a greater number
of women seem to develop metastatic disease versus men:
40% versus 25%; but these numbers were reversed in this
clinical study: 15% versus 40%. This may suggest, how-
ever, that tumor histologic type may be more of a factor in
prognosis than gender, as our series had more men with
adenoid cystic carcinoma than women, and the same is true
for the literature: 74% of reported cases in women were
adenoid cystic carcinoma versus 65% for men.
It seems that radiation treatment does not necessarily
change the ultimate outcome of patients, but may provide
for a longer overall survival. In this clinical study, 50% of
patients treated by radiation died of disease (mean,
4.2 years) and 50% showed no evidence of residual disease
(mean, 14.3 years). Patients reported in the literature reﬂect
similar ﬁndings: overall, 43 patients did not receive radia-
tion (mean overall survival, 5.9 years) while 29 patients
received radiation (mean overall survival, 5.7 years). Spe-
ciﬁcally, of the patients treated with radiation: 37.9% died
of disease (mean, 5.0 years) versus 48.2% with no evidence
of disease (mean, 4.5 years). Radiation therapy is used more
frequently in ceruminous adenocarcinoma, NOS cases than
in ceruminous adenoid cystic carcinoma. Therefore, radia-
tion probably has a role in palliation or applied at the time
recurrence develops, but not necessarily at the time of initial
diagnosis, except perhaps for the ceruminous adenocarci-
noma, NOS group [4, 5, 10, 29, 70, 73].
Adenoid cystic carcinoma has a deceivingly favorable
early prognosis, but many patients will eventually succumb
to the disease. In these patients, the average period from the
onset of symptoms to death is over 9 years. Therefore, it is
imperative that all ceruminous malignancies be followed
for many years after their initial presentation. Distant
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bones have been reported, and metastases tend to maintain
their primary histological identity [4, 10, 14, 17, 29, 50,
53]. Interestingly, we did not detect any lymph node
metastases in this clinical series, and it is only rarely
reported, suggesting that local recurrence and/or distant
metastasis is more likely than lymph node metastases.
Review of the literature shows that mucoepidermoid car-
cinoma has a poor outcome (mean follow-up, 1.5 years),
with 3 of 5 patients dead of disease, and follow-up limited
to 2.2 years in the remaining two patients [17, 39, 54, 62].
Staging was not applied to these tumors, as we were not
the primary treatment facility. We did not have access to
radiographic studies or full operative reports to be able to
determine extent of soft tissue or bone involvement and
whether there was facial paralysis at presentation. There is
a proposed staging for external auditory canal squamous
cell carcinoma based on clinical and computed tomogra-
phy ﬁndings by authors from the University of Pittsburgh
[74]. While there may be some overlap, this staging is
based on extent of invasion (limited to the epidermis,
\0.5 cm soft tissue invasion,[0.5 cm soft tissue invasion,
bone invasion), features which cannot be employed in
ceruminous neoplasms, which by deﬁnition are arising
from dermal glands, eliminating pT1 through T3 as
potential categories.
Differential Diagnosis
Axiomatic, clinical and radiographic exclusion of a sali-
vary gland origin (parotid gland) must be accomplished in
order to produce appropriate management. Pathological
diagnosis rests on the adequacy of the initial biopsy. If the
biopsy is too limited, a deﬁnitive diagnosis cannot be
reliably generated. The differential diagnosis includes
pleomorphic adenoma (benign mixed tumor), middle ear
adenoma, and low-grade adenocarcinoma of the middle
ear. The dual cell population of a pleomorphic adenoma
(whether of the ceruminous glands or from the parotid
gland) may cause difﬁculty in achieving a correct diagnosis
of a ceruminous gland adenoma. However, decapitation
secretions are not identiﬁed and the background stroma is
myxoid-chondroid rather than ﬁbrotic [35]. A neuroendo-
crine adenoma of the middle ear (middle ear adenoma) also
has a dual cell population, but demonstrates a ﬁnely stip-
pled nuclear chromatin distribution and lacks decapitation
secretions. Further, the immunohistochemical proﬁle of
chromogranin and human pancreatic polypeptide is unique
[75]. Cellular pleomorphism can be seen in ceruminous
adenoma and middle ear adenocarcinomas can be quite
cytologically bland. However, true middle ear adenocar-
cinomas are very uncommon, and will frequently
demonstrate deﬁnitive invasion of bone, cartilage, vascular
channels or perineural spaces by the tumor cells. These
tumors arise within the middle ear mucosa and show
tympanic membrane destruction or erosion, as well as
extension down the eustachian tube. Sometimes separation
may require radiographic and clinical correlation.
Ceruminous adenoid cystic carcinoma may occasionally
be mistaken for a primary skin tumor, speciﬁcally basal
cell carcinoma. The histologic appearance on small biop-
sies may be identical. Therefore, it is important to consider
whether the tumor is ‘‘involving’’ the epidermis versus
‘‘arising’’ from it. In some cases, excision may be the only
way to make this separation accurately.
Summary
Ceruminous carcinomas are rare malignancies usually
presenting with a mass or pain in the outer ear canal of
middle aged patients. Tumors are large for the anatomic
site. They demonstrate an inﬁltrative pattern with moderate
to severe nuclear pleomorphism, increased mitotic ﬁgures
and rarely necrosis. The tumor are classiﬁed as ceruminous
adenocarcinoma, NOS, ceruminous adenoid cystic carci-
noma and ceruminous mucoepidermoid carcinoma.
Diagnostic difﬁculties are frequently encountered by the
pathologist, especially when the samples are small. Prog-
nosis may be difﬁcult to predict, but complete surgical
excision coupled with radiation yields the best long-term
prognosis. Ceruminous adenoid cystic carcinoma has a
prolonged course, with metastatic disease after recurrences
in approximately 50% of patients, but many years after the
initial tumor’s excision.
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